SCHEMBL6477392

SCHEMBL6477392

CCCOc1cc2c(cc1-c1cc(/C=C/C(=O)OCC)ccc1OCOC)C(C)(C)CCC2(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.51
ACHE P22303 4/20 0.44
BCHE P06276 3/20 0.44
MAOB P27338 1/20 0.43
KDM4E B2RXH2 1/20 0.42
RXRA P19793 5/20 0.41
TTR P02766 1/20 0.41
DPP4 P27487 1/20 0.41
APP P05067 2/20 0.40
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
RARG P13631 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477393 1.00 FDPS (0.51) FDPSACHEBCHEMAOBKDM4E
SCHEMBL6473188 0.95 FDPS (0.49) FDPSACHEBCHEMAOBRXRA
SCHEMBL6473192 0.95 FDPS (0.49) FDPSACHEBCHEMAOBRXRA
SCHEMBL6476811 0.92 FDPS (0.53) FDPSACHEBCHEMAOBKDM4E
SCHEMBL6476815 0.92 FDPS (0.53) FDPSACHEBCHEMAOBKDM4E
SCHEMBL6472485 0.90 KDM4E (0.54) ACHEKDM4ERXRARARARARB
SCHEMBL6472482 0.90 KDM4E (0.54) ACHEKDM4ERXRARARARARB
SCHEMBL6472649 0.89 RXRA (0.54) FDPSACHEBCHEMAOBRXRA
SCHEMBL6472653 0.89 RXRA (0.54) FDPSACHEBCHEMAOBRXRA
SCHEMBL6472405 0.89 KDM4E (0.47) FDPSKDM4ERXRATTRAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R FDPS 3696/4885ACHE 2858/4885BCHE 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.